Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Roche Eyes More Growth Opportunities For Vabysmo

Ophthalmology Drug Sales Soar In Q2

Jul 27 2023

• By Kevin Grogan

Terea Graham — Teresa Graham • Source: Roche

Related Content

Clinical Hold For Merck KGaA’s BTK Inhibitor Evobrutinib For MS Raises Class Safety Fears

Apr 12 2023

Eyebrows Raised As Roche Inks Cardiovascular Pact With Alnylam

Jul 24 2023

Roche Touts 10-Minute Ocrevus Benefits For MS

Jul 13 2023

Regeneron’s CRL For High-Dose Eylea Benefits Roche, Vabysmo

Jun 28 2023

Questions About Gantenerumab Failure Remain, But Roche Is Not Yet Finished With Alzheimer’s

Nov 28 2022

Related Companies

Roche Holding AG

Bayer AG

Regeneron Pharmaceuticals, Inc.

Merck KGaA

Alnylam Pharmaceuticals Inc.

Additional Topics

Sales & Earnings Business Strategies Commercial Ophthalmic BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.